Avalo Therapeutics, Inc. (AVTX): M&A transaction — Avalo completes divestiture of AVTX-800 series for $150K upfront, up to $45M milestones

Avalo Therapeutics, Inc.

Upfront payment of $150,000 from AUG; AUG assumed $150,000 of pre-closing liabilities.
Potential aggregate milestone payments of $45M ($15M per compound) upon first FDA approval for non-Rare Pediatric Disease.
AUG to share up to 20% of net proceeds from any future sale of priority review vouchers.
CEO states pipeline now focused on core immunology assets; transaction immediately improves cash flow.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Avalo Therapeutics, Inc. completed a disposition involving AUG Therapeutics, LLC for $150,000 upfront plus contingent milestone payments (closed 2023-10-27).

Action: disposition
Counterparty: AUG Therapeutics, LLC
Consideration: $150,000 upfront plus contingent milestone payments
Closing: 2023-10-27

Exact text from the filing

previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023 (the Purchase Agreement). AUG paid an upfront payment of $150,000, as well as, for each compound, is obligated to make a contingent milestone payment of $15,000,000 (for a potential aggregate of $45 million) if the first Food and Drug

View on SEC.gov

68 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-035600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.